Capital raising and dilution risk
The company may need external funding to support R&D, commercialization, and operations.
- Scope
- Equity holders
- Materiality
- high
Pluri Inc.
Pluri Inc. is a biotechnology company built around a proprietary 3D cell expansion platform used to develop cell-based products and manufacturing services. Through subsidiaries and collaborations, it applies this platform across regenerative medicine, immunotherapy, cultivated food ingredients, coffee and cacao, and cell therapy CDMO services, with operations rooted in the United States, Israel, and Germany.
−1 636,2 %
49,0 %
−1 690,3 %
+309,8 %
0.68
0.68
| % | |
|---|---|
| Cell expansion platform | 0% Proprietary 3D technology used to expand cells at industrial scale for multiple applications. |
| CDMO services | 55% Process development, manufacturing, and analytical testing for cell therapy customers. |
| Regenerative medicine and immunotherapy | 15% Cell-based therapeutic programs and related development activities. |
| Cultivated food ingredients | 20% Cell-based food products and ingredients, including cultivated coffee and cacao. |
| AgTech collaborations | 10% Cell-based agricultural applications, including biostimulants and crop-related POCs. |
Pluri sells primarily to pharmaceutical and biotech companies that need outsourced cell therapy development and...
- Pharmaceutical and biotech companiesprimary
Buy cell therapy CDMO services such as process development, manufacturing, and analytical testing.
- Food-tech and cultivated ingredient partnerssecondary
Work with Pluri on cultivated coffee, cacao, and other cell-based food ingredients.
- Agriculture and agtech partnerssecondary
Use the platform for biostimulants, crop-related proof-of-concepts, and sustainable agriculture applications.
- Research and collaboration partnerssecondary
Participate in clinical, technical, and commercial collaborations around cell-based technologies.
Pluri is incorporated in Nevada but its operating footprint is centered in Israel, where several subsidiaries are based...
- •United States: corporate domicile, capital markets listing, and customer access
- •Israel: main subsidiary base and core operating hub for development
- •Germany: European subsidiary supporting regional operations and collaborations
- •Europe: clinical and regulatory activity, including consortium-based studies
- •Global: food-tech and agtech partnerships can extend beyond one market
Pluri’s strategy is to monetize its cell expansion platform across multiple end markets rather than depend on a single...
01
Scale CDMO servicesshort-term
CDMO work provides a commercial path for the platform while supporting pharma and biotech customers.
02
Develop cultivated food businessesmedium-term
Coffee and cacao programs extend the platform into large consumer ingredient markets.
03
Expand platform licensing and collaborationsmedium-term
Partnerships can monetize the technology without requiring full downstream commercialization.
Pluri faces the typical risks of an early commercial biotechnology platform: long development cycles, regulatory...
Nasdaq continued listing risk
Failure to meet listing standards could pressure the share price and reduce access to capital.
- Scope
- Public market liquidity
- Materiality
- high
Regulatory and clinical development risk
Cell therapy and related programs depend on approvals, trial execution, and compliance.
- Scope
- Therapeutic pipeline
- Materiality
- high
Commercialization risk for new verticals
Cultivated coffee, cacao, and agtech products may take time to reach scale and acceptance.
- Scope
- Food and agriculture ventures
- Materiality
- medium
Manufacturing and quality risk
The business depends on GMP-like manufacturing discipline and reproducible cell expansion.
- Scope
- CDMO and product development
- Materiality
- medium
Cybersecurity and data loss risk
Clinical and development programs rely on sensitive data and third-party systems.
- Scope
- Clinical operations
- Materiality
- medium
Revenue recognition over time
Can shift revenue between periods as project estimates change
Goodwill and intangible assets
Potential non-cash write-downs if expected value declines
Share-based compensation
Affects operating expenses and diluted share count
Foreign currency exposure and hedging
Can create gains/losses and hedge accounting complexity
Acquisition purchase accounting
Changes future amortization and impairment profile
Calidi Biotherapeutics, Inc.
CLDI · Biological Products, (No Diagnostic Substances)
Lunai Bioworks Inc.
LNAI · Pharmaceutical Preparations
Trevi Therapeutics, Inc.
TRVI · Pharmaceutical Preparations
Absci Corp
ABSI · Services-Commercial Physical & Biological Research
Absci Corp is a biotechnology company built around its Integrated Drug Creation platform, which combines AI-driven design, wet-lab biology, and computational…
SUTRO BIOPHARMA, INC.
STRO · Biological Products, (No Diagnostic Substances)
Sutro Biopharma is a U.S.-based biopharmaceutical company that develops therapeutic biologics using its XpressCF® and XpressCF+® cell-free protein synthesis platforms.
Celularity Inc
CELU · Pharmaceutical Preparations
: 29/04/2026